History of the early development of aromatase inhibitors for treatment of breast cancer
These studies provided definitive evidence of the superiority of aromatase inhibitors over tamoxifen in postmenopausal women with hormone responsive breast cancer.
The early development of aromatase inhibitors for the treatment of hormone‑responsive breast cancer was guided by the Penn State Hershey collaborative group. Initial observations with aminoglutethimide (AG) combined with hydrocortisone (HC) demonstrated significant tumour regression in post‑menopausal women. Subsequent mechanistic studies confirmed that AG blocked aromatase activity by 95–98 %, establishing it as the first selective aromatase inhibitor. Randomised controlled trials showed that AG/HC medical ‘adrenalectomy’ was not inferior to surgical adrenalectomy or to tamoxifen, proving the superiority of aromatase inhibition in this patient population.
The demonstration that aromatase inhibitors outperform tamoxifen established a new standard of care for post‑menopausal women with estrogen‑receptor‑positive breast cancer, leading to widespread clinical adoption of these agents.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC